Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2024 Apr;59(4):564-565. doi: 10.1038/s41409-024-02201-w. Epub 2024 Jan 23.

Authors

Saffiya Z Bashey¹, Scott R Solomon², Xu Zhang³, Lawrence E Morris², H Kent Holland², Lizamarie Bachier², Melhem M Solh⁴

Affiliations

¹ The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
² Blood and Marrow Transplant Program at Northside Hospital, Atlanta Georgia, GA, USA.
³ Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.
⁴ Blood and Marrow Transplant Program at Northside Hospital, Atlanta Georgia, GA, USA. msolh@bmtga.com.

PMID: 38263393
DOI: 10.1038/s41409-024-02201-w

No abstract available

Publication types

Letter

MeSH terms

Acetates*
Antiviral Agents / therapeutic use
Cytomegalovirus
Cytomegalovirus Infections* / drug therapy
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Incidence
Quinazolines*

Substances

letermovir
Antiviral Agents
Acetates
Quinazolines